drugset / Trial / NCT00335439

Effect of Prophylactic Ketorolac on CME After Cataract Surgery

NCT00335439

Completed 98 enrolled Queen's University
RandomizedSingle-groupOpen-labelPrevention

Summary

The study will evaluate the efficacy of prophylactic administration of the topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac tromethamine 0.5% (Acular®) on cystoid macular edema (CME) in patients having undergone cataract surgery. CME is the most frequent cause of decreased vision after uncomplicated cataract surgery and can result in irreversible sight reduction. The investigation will involve a comparison arm and a treatment arm with both sets of patient populations being evaluated for CME with ophthalmologic examinations and optical coherence tomography (OCT) measurements. The objective is to elucidate the role of NSAID drops in preventing CME after cataract surgery.

Timeline

Start
2006-06
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Tromethamine Small molecule 0.5 % Topical

Indications